Generic Name and Formulations:
Bromfenac 0.07%; oph soln; contains benzalkonium chloride, sulfites.
Bausch & Lomb Inc.
Indications for PROLENSA:
Post-operative inflammation and reduction of ocular pain following cataract surgery.
>18yrs: 1 drop into the affected eye once daily beginning 1 day prior to surgery, continued on the day of surgery, and through the first 14 days post-op. May be given with other topical ophthalmics (eg, alpha-agonists, beta-blockers, carbonic anhydrase inhibitors, cycloplegics, mydriatics); administer at least 5 minutes apart.
<18yrs: not established.
Sulfite sensitivity. Asthma. May slow or delay wound healing. Bleeding tendencies. Corneal defects/denervation. Ocular surface diseases. Rheumatoid arthritis. Diabetes. Monitor cornea; discontinue if corneal epithelial breakdown occurs. Risk of corneal adverse events may be increased if used >24hrs before surgery, or beyond 14-days post-op. Contact lenses (remove prior to therapy). Pregnancy (avoid during late pregnancy). Nursing mothers.
Concomitant topical corticosteroids may potentiate healing problems. Caution with concomitant drugs that prolong bleeding time.
Anterior chamber inflammation, foreign body sensation, eye pain, photophobia, blurred vision; keratitis, corneal reactions (eg, epithelial breakdown, thinning, erosion, ulceration/perforation).
- 3ml of 0.07% eye droppers (Qty:1)
- appx. price $206.00
- Over 50 FDA-Approved Meds Could Treat Ebola Infection
- Pharmacy Employees Arrested, Charged in Meningitis Outbreak
- How Effective Are Neuraminidase Inhibitors in Containing Flu?
- Ondansetron, Tramadol Drug Interaction Identified
- Pain Management in Patients with IBD: Individualizing Treatment Approaches